Valeant says it can't justify matching Actavis offer for Allergan
MLex Summary: Valeant Pharmaceuticals said in a statement Monday it can't justify matching Actavis' bid for Botox maker Allergan, according to an Allergan filing with the Securities and Exchange Commission. Valeant will...To view the full article, register now.
Already a subscriber? Click here to view full article